Listed medical device company Creo Medical has appointed David Woods as CCO from his previous role as Non-Executive Director.

Founded in 2003, the firm has headquarters in Chepstow, with a second office in Bath. The medical device company focuses on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy.

Woods brings experience in the MedTech sector and joins the company in his new full-time executive role based in the USA, having previously been the President and CEO of PENTAX Americas and M&A Director of HOYA Group PENTAX Medical.

His appointment is hoped to benefit the Creo team “at a crucial time when the Company is moving from early clinical adoption to global commercialisation expansion”, said the firm.

As CCO, he will provide leadership and strategic direction for Creo’s Group Commercial divisions overseeing all strategic global commercial activities, which are key to Creo’s growth.

Its US growth news also includes the appointment of a President of Sales, Service and Commercial Operations, who will operate in both the USA and the Asia-Pacific regions.

These appointments, along with other recent appointments, bring with them experience from companies such as Medtronic, Covidien, BARRX, J&J, Pentax, Philips Healthcare, US Endoscopy, and BTG Group.

The company said it is looking to grow the US based team for market and sales development as well as increase the UK based team for business management coverage throughout the UK and EU, and for the key delivery of sales and service operations in all regions.

Craig Gulliford, CEO of Creo, commented: “Dave [Woods] has been working with Creo since 2015 and we are delighted that he will be joining us full-time as Chief Commercial Officer, during a key phase in the Company’s development as we look to commercialise our wider range advanced energy products. Dave brings with him a wealth of experience in the med-tech sector having been a key driver of the PENTAX Medical Americas team for more than 20 years.

“Dave has been a great support as a Non-Executive and his decision to join us full-time speak volumes for the commercial opportunity we have before us across multiple applications for our technology. Despite the COVID-19 climate, over the last six months we have been able to attract some terrific commercial talent in addition to Dave joining full time.

“These senior management additions are fundamental as we expand our commercialisation and come at an exciting time as we launch a range of innovative devices to improve patient outcomes globally.”

In Many the firm signed a commercialisation agreement with the Department of Health and Social Care to provide NHS Hospitals with its technology.